Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) is a pioneering clinical-stage gene therapy company committed to transforming the landscape of cancer and diabetes treatments. The company's mission is to address the unmet medical needs of a growing population of patients worldwide through the development of innovative immunogene therapies. Genprex's flagship product, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is at the forefront of its oncology program and is currently being evaluated in three clinical trials targeting non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Oncoprex® Delivery System, Genprex's proprietary platform, encapsulates gene-expressing plasmids using lipid-based nanoparticles. This systemic, non-viral method enables the intravenous delivery of tumor suppressor genes to cancer cells, which then express proteins that were deficient in the tumor. Reqorsa Immunogene Therapy has shown promise by re-establishing pathways for programmed cell death, interrupting cancer cell signaling, and modulating immune responses.
The company's recent achievements include securing new patents and receiving FDA Fast Track and Orphan Drug designations for its clinical programs. Specifically, the Acclaim-2 and Acclaim-3 studies are exploring the potential of Reqorsa in combination with immune checkpoint inhibitors like Keytruda® and Tecentriq®. These trials aim to provide new therapeutic options for patients with advanced-stage lung cancers who have limited treatment alternatives.
In addition to its oncology initiatives, Genprex is advancing a novel gene therapy approach for diabetes. Using an AAV vector, the company delivers Pdx1 and MafA genes directly to the pancreas to transform alpha cells into beta-like cells capable of producing insulin. This method shows promise for both Type 1 and Type 2 diabetes and aims to offer a new lifeline for patients with these conditions.
Genprex collaborates with renowned institutions and industry leaders to further its research and development pipeline. The company's commitment to innovation and patient-centric solutions positions it as a significant player in the gene therapy landscape.
Latest News:
- March 12, 2024 - Genprex announces new patent grants in South Korea for Reqorsa® Immunogene Therapy.
- March 19, 2024 - Genprex enters into agreements for the sale and issuance of shares, expecting gross proceeds of $6.5 million.
- April 2, 2024 - Positive preclinical data for NPRL2 gene therapy presented at AACR Annual Meeting.
- April 3, 2024 - Multiple new trial sites added for Acclaim-3 study in extensive-stage small cell lung cancer.
- April 9, 2024 - Research collaborators present positive preclinical data supporting Reqorsa and NPRL2 therapies.
- May 8, 2024 - Genprex announces the passing of its co-founder and CEO Rodney Varner.
- May 14, 2024 - First patient dosed in Phase 1 of Acclaim-3 clinical study for Reqorsa® and Tecentriq® combination therapy.
Genprex, Inc. (GNPX) announced that the USPTO granted U.S. Patent No: 11,278,592 B2, covering methods for using REQORSA Immunogene Therapy in combination with immune checkpoint inhibitors until 2038. This patent is crucial for protecting their therapy involving Keytruda® for treating non-small cell lung cancer (NSCLC). The ongoing Acclaim-2 Phase 1/2 clinical trial evaluates REQORSA with Keytruda in patients whose cancer progressed after Keytruda treatment, with the Phase 1 portion set to enroll up to 30 patients by mid-2023.
Genprex (NASDAQ: GNPX) announced the Safety Review Committee's approval to advance the Acclaim-1 Phase 1/2 trial of REQORSA™ in combination with Tagrisso® for late-stage non-small cell lung cancer (NSCLC). This decision follows a review of the first cohort, highlighting REQORSA's safety profile. The trial aims to determine the maximum tolerated dose, with enrollment expected to complete the Phase 1 by year-end.
The SRC's decision marks a significant milestone for Genprex, supporting its goal of providing innovative therapies for patients with limited options.
Genprex, Inc. (NASDAQ: GNPX) announces that its manufacturing leadership will present at the Next Generation Lipid-Based Nanoparticles Delivery Summit from July 19-21, 2022, in Boston. Hemant Kumar, Chief Manufacturing and Technology Officer, will discuss innovative gene therapy techniques. Genprex is advancing its lead program targeting non-small cell lung cancer with its proprietary ONCOPREX® Nanoparticle Delivery System. The FDA has granted Fast Track Designation for its lead candidate, REQORSA™, in combination therapies for cancer patients.
On June 2, 2022, Genprex announced its participation in two key investor conferences. The LD Micro Invitational will be held from June 7-9, with Genprex's presentation on June 8 at 4:00 PM PT, led by CFO Ryan Confer. The BIO International Convention is set for June 13-16, with a presentation by EVP Catherine Vaczy on June 14 at 3:30 PM PT. Genprex focuses on gene therapies for cancer and diabetes and uses the ONCOPREX Nanoparticle Delivery System for its lead candidate REQORSA, currently in clinical evaluation for non-small cell lung cancer.
Genprex, Inc. (NASDAQ: GNPX) announced a virtual presentation led by President and CEO Rodney Varner at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. Varner will showcase the company's innovative gene therapies for cancer and diabetes, available on-demand from May 24. Genprex focuses on life-changing therapies, featuring its ONCOPREX® Nanoparticle Delivery System for cancer treatment and its lead candidate, REQORSA™, aimed at non-small cell lung cancer (NSCLC). The FDA has granted Fast Track Designation for REQORSA in combination therapies with Tagrisso® and Keytruda®.
Genprex, Inc. (NASDAQ: GNPX) announced that its Chief Medical Officer, Mark Berger, M.D., will participate in the 33rd Annual Cancer Progress Conference on May 12, 2022. The virtual panel discussion, titled "Into the Unknown – Bringing New Modalities into Solid Tumors," will focus on the positioning of cell-based and emerging immunotherapy platforms in solid tumors. Genprex is a clinical-stage gene therapy company aiming to create innovative therapies for cancer and diabetes, utilizing its ONCOPREX® Nanoparticle Delivery System for its lead product candidate, REQORSA™, targeting non-small cell lung cancer.
Genprex, Inc. (NASDAQ: GNPX) has made significant advancements in its clinical programs in 2022. The company commenced patient treatment in the Phase 1/2 Acclaim-2 trial for non-small cell lung cancer (NSCLC) and received a second Fast Track Designation for its product REQORSA™ Immunogene Therapy. Additionally, Genprex has expanded its pipeline to include small cell lung cancer. CEO Rodney Varner expressed optimism about the company’s future as it pursues innovative gene therapy solutions for patients with serious health conditions.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced its participation in key conferences focused on its innovative therapies for cancer and diabetes. The presentations will be held during NobleCon 18 from April 19-21, 2022, with a specific session on April 20 at 11:30 a.m. ET. Additionally, Genprex will feature in the Alliance for Regenerative Medicine's virtual meeting from April 20-22, 2022. These events are crucial for showcasing Genprex's proprietary ONCOPREX® Nanoparticle Delivery System and the lead candidate, REQORSA™, targeting non-small cell lung cancer.
Genprex, Inc. (GNPX) announced the opening of patient enrollment for its Acclaim-2 clinical trial, evaluating the combination of REQORSA™ Immunogene Therapy and Keytruda® in late-stage non-small cell lung cancer (NSCLC) patients. This follows Genprex's prior FDA Fast Track Designation for similar treatments. The trial aims to establish the maximum tolerated dose and assesses the synergistic effects of the combination on progression-free survival. An interim analysis is planned after 50 events, with expectations to complete the Phase 1 portion by Q1 2023.
Genprex, a clinical-stage gene therapy company, will present at the BIO Europe Spring Investor Conference from March 28-31, 2022. President and CEO Rodney Varner will discuss the company's innovative gene therapies targeting cancer and diabetes. Genprex's lead product, REQORSA (quaratusugene ozeplasmid), aims to treat non-small cell lung cancer by utilizing the ONCOPREX Nanoparticle Delivery System, which is the first systemic gene therapy for cancer in humans. The presentation will be available on-demand, and Varner will also engage in virtual one-on-one meetings with participants.
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
What is Genprex's main focus?
What is Reqorsa Immunogene Therapy?
How does the Oncoprex® Delivery System work?
What recent achievements has Genprex made?
What is the status of Genprex's clinical trials?
What are the implications of Genprex's recent patent grants?
What is Genprex's approach to diabetes treatment?
How does Reqorsa enhance current cancer treatments?
Who are Genprex's key collaborators?
How has Genprex adapted to recent leadership changes?
